Highly active antiretroviral therapy (HAART) treatment for HIV has changed the course of AIDS in societies in which the drugs are readily available. Despite the great success of HAART, drug resistance and toxicity issues still remain a concern for some individuals. Thus, a number of investigators have been exploring other approaches for inhibiting HIV-1 replication. One of the most potent of these is the use of RNA interference (RNAi). This review will focus solely on the use of RNAi for the treatment of HIV-1 infection, including the problems, progress and future prospects.
POTENTIAL MOLECULAR TARGETS FOR ANTI-HIV RNAi THERAPEUTICS
HIV-1 chronically infects individuals, thus requiring long-term RNAi treatment. To achieve potent and durable suppression of viral replication, the viral RNA genome or host cellular transcripts that encode proteins essential for viral replication can be used as anti-HIV targets. Development of viral resistance is a common setback with HIV therapies because of the generation of viral escape mutants. It has been demonstrated that prolonged infection of cells harboring genes encoding anti-HIV siRNAs can result in the evolution of escape variants that are resistant to the expressed siRNA. 12, 13 A single-nucleotide mutation in a critical position within the target sequence relative to the siRNA site of interaction as well as mutations, which results in other structural changes or elimination of the target region, can diminish and/or eliminate RNAi-mediated inhibition. 13 Thus, a single siRNA therapy is not sufficient to maintain long-term inhibition of virus replication. One of the strategies for achieving the desired RNAi long-term efficacy is mitigating viral escape from RNAi 14, 15 through multiple RNAi effectors akin to the highly active antiretroviral therapy (HAART) 16 approach. It is also important to target sequences that are conserved among different virus strains to reduce the chance of mutant escape and to multiplex siRNAs to several different viral sequences to reduce the probability of viral escape. Host factors that are essential for viral replication can also be targeted, which may reduce the chance of viral escape.
To date, numerous siRNAs targeting a number of HIV-1 or cellular transcripts have been demonstrated to achieve viral inhibition both in vitro and in vivo. Indeed, all the HIV-1-encoded genes (tat, rev, gag, pol, nef, vif, env, vpr and the long terminal repeat) are susceptible to RNAi-induced gene silencing in cell lines. 17 For example, the Tat and Rev proteins are essential for subsequent expression of HIV-1 structural genes (gag, pol and env) and for the synthesis of full-length viral genomic RNA. 18 Small interfering RNAs designed to destroy the tat/rev transcripts were found to be highly effective in viral suppression. 19 Several well-known host factors, including nuclear factor kappa b, the CD4 receptor and the coreceptors CCR5 (C-C motif receptor 5) and CXCR4 (C-X-C motif receptor 4) have been successfully targeted by siRNAs, thereby suppressing viral replication or entry. 10 Recently, three siRNA-screening studies have been conducted to identify hundreds of host factors that are critical for HIV replication. [20] [21] [22] Brass et al., 20 using a large-scale siRNA screen identified 273 genes whose depletion inhibited either p24 production or viral gene activities. There were some surprises among these targets, such as Rab6 (a regulator of retrograde protein transport to the Golgi), transportin 3-SR2 (TNPO3, a nuclear import factor for serine/arginine-rich (SR) substrates) and Med28 (the mediator of transcription activation complex component). Specifically, depletion of Rab6 or transportin 3 potently blocked early stages of virus infection. The compilation of hits in the three screening analyses differed because of the conditions (cell types and types of infectious challenges) and readouts of the screens. Nevertheless, these screening approaches have opened up a new landscape of viral-host interactions that are potential targets for RNAi. 23 Similar to the conventional HAART strategy, using multiple siRNAs targeting separate, conserved sites in HIV along with targeting HIV host-dependency factors has been shown to minimize and even prevent escape while achieving prolonged inhibition. 24 In this regard, host factors that are essential for viral entry and replication represent attractive molecular targets. Host genes such as the chemokine receptor CCR5 can be targeted alone or in combination with viral sequences in a tailored manner to reduce the possibility of viral escape mutants and to avoid toxicity risks associated with long-term HAART treatment. 10, 15 SYSTEMIC DELIVERY OF siRNAs FOR HIV TREATMENT Although siRNAs hold great therapeutic promise for HIV/AIDS, their clinical application has been and still is limited by difficulties of delivering siRNAs in the bloodstream to the right target cells. 25, 26 In practice, all HIV-susceptible cells such as, human T cells and monocytes are difficult targets for siRNA delivery. Therefore, efficient, systemic delivery of siRNAs in vivo, especially targeted siRNA delivery to HIV-1 susceptible or infected cells, remains a principal challenge for successful anti-HIV therapeutic application. Several recent studies using targeted delivery approaches provide encouragement that this obstacle could soon be overcome (Figure 1 ).
Single-chain antibody-siRNA chimeras targeting either the T-cell CD7 (cluster of differentiation 7) receptor 27 or gp120-expressing cells have been shown to functionally deliver anti-HIV siRNAs in vivo. 28 CD7, a human transmembrane protein on thymocytes and the majority of human T cells, has been documented to be rapidly internalized after antibody binding. 29 With this in mind, an anti-CD7 monoclonal antibody and its recombinant single-chain (ScFvCD7) fragment have been exploited for targeted delivery.
Kumar et al. 27 successfully conjugated a Cys-modified scFvCD7 with an oligo-9-arginine peptide to obtain a cell-type-specific siRNA delivery system (ScFvCD7-9R). In this case, a combination of three siRNAs against two conserved HIV-1 genes (vif and tat) and the cellular CCR5 coreceptor was formulated with scFvCD7-9R system. The complex was systemically administered to HIV-1-infected humanized mice. The weekly injections suppressed endogenous virus and restored CD4+ T-cell counts in the viremic mice.
HIV-1 gp120 glycoprotein is exposed on the surface of virus particles and the plasma membrane of HIV-1-infected cells, which thus represents a marker to distinguish HIV-1-infected cells from uninfected cells. 30 F105, an anti-HIV-1 gp120 monoclonal antibody, has been demonstrated to bind with high affinity to its ligand gp120, expressed on the surface of a wide range of HIV-1 laboratory strains and primary isolates. 31 Song et al. 28 used a heavy-chain fragment of F105 to promote receptor-specific internalization to the cells expressing the HIV-1 envelope protein. In this system, the F105 antibody fragment was fused with protamine. The resulting fusion protein can specifically bind to HIV-1-infected primary T cells. In addition, the siRNA targeting the HIV-1 gag capsid gene delivered by the fusion protein, suppressed HIV-1 replications only in HIV-1 envelope expressing cells.
Selective targeting and delivery of an anti-CCR5 siRNA to lymphocytes in vivo has been demonstrated using nanoparticles harboring the lymphocyte function-associated antigen-1. 32 Lymphocyte functionassociated antigen-1, the predominant integrin present on all leukocytes has been used to selectively deliver siRNAs to multiple immune cell types, including T cells, macrophages and dendritic cells that have key roles in HIV infection and pathogenesis. In vivo administration of the lymphocyte function-associated antigen-1 integrin-targeted immunoliposome-anti-CCR5 siRNA nanoparticles resulted in selective uptake of siRNA and specific gene silencing by T cells and macrophages, further protecting humanized mice from HIV challenge with an enhanced resistance to infection.
An RNA aptamer that binds to the HIV envelope protein gp120 expressed on the surface of HIV-infected cells has also been used for functional siRNA delivery in vivo. 33 These studies demonstrated that 2¢-fluoro-modified RNA aptamers that specifically Highly active antiretroviral therapy J Zhou and JJ Rossi bind HIV-1 gp120 and are rapidly internalized into HIV-1-infected cells can neutralize HIV-1 replication. 34, 35 Recently, our group has successfully used an anti-HIV-1 gp120 aptamer for cell type-specific delivery of anti-HIV dicer-substrate RNAs in HIV-1-infected, humanized Rag-hu mice. 33 The anti-gp120 aptamer has dual functions, serving as an HIV-neutralizing agent and as a targeted delivery vehicle for siRNAs. The gp120 aptamer-siRNA chimera was systemically administered once a week into viremic animals for several weeks. The treatments resulted in several logs of suppression of HIV-1 viral loads. As expected, the anti-HIV-1 tat/rev dicer-substrate RNA, delivered by the aptamer, was processed by Dicer, leading to incorporation into the RNA-induced silencing complex and target mRNA cleavage in vivo.
As mentioned above, the rapid emergence of viral escape mutants often abrogates RNAi efficacy. Therefore, continued efforts also have been made to develop an aptamer-mediated delivery of combinatorial RNAi therapeutics. 34 A single HIV-1 gp120 aptamer was tightly complexed with three different dicer-substrate RNAs targeting HIV-1 tat/rev or the host dependency factors (CD4 and transportin-3). Such a combination of aptamer and cocktailed siRNAs has the added benefits of mitigating the emergence of viral escape mutants.
A different aptamer that binds to the CD4 receptor and internalizes was shown to be an effective mucosal microbicide. 36 CD4 is well known as the primary receptor for the HIV and has an important role in the HIV entry into host T cells. [37] [38] [39] CD4 targeting RNA aptamers have blocked HIV-1 and CD4 interactions, and have proven to be useful anti-HIV agents. 40 CD4 aptamer-siRNA chimeric RNAs were used to specifically deliver siRNAs to CD4 + cells and inhibit target gene expression in vitro, as well as in cervicovaginal tissue explants. 36 When applied intravaginally in a humanized mouse model, the CD4 aptamer-siRNA chimeric RNAs bearing siRNAs targeting HIV gag and vif or host CCR5 significantly prevented viral transmission to cervicovaginal explants and to the mice.
Thus far in humanized mice at least, cell-type-specific delivery of siRNAs for the treatment of HIV-1 infection seems to be working quite well. The next challenges will be to use these approaches in nonhuman primates to validate safety and efficacy.
GENE THERAPY-MEDIATED DELIVERY OF SHORT-HAIRPIN RNAs (shRNAs)
The alternative to systemic siRNA delivery is to use ex vivo gene therapy to deliver integrating or nonintegrating viral vectors harboring transcription units that express short-hairpin RNAs (shRNAs) targeting HIV-1 or cellular sequences required for HIV-1 infection (Figure 2) . The concept of gene therapy for the treatment of HIV-1 infection received a huge boost with the demonstration that HIV-1 infection was eradicated from an AIDS/leukemia patient who received an allogeneic hematopoietic stem cell transplant from a donor who had a homozygous deletion in the chemokine receptor gene CCR5. 41 It is known that CCR5 is a primary coreceptor for HIV-1 entry, hence, in effect the transplant patient was given a protective therapy. Although this is a single patient result, the idea that repopulation of the hematopoietic system with cells resistant to HIV-1 infection can have a major impact on the disease is now a reality. Finding CCR5 À/À -compatible donors is a major challenge and, as such, this cannot be considered to be a treatment that will have broad applications. In addition, virus that mutates to CXCR4 tropism can infect the CCR5 À/À cells and reactivate the infection. Thus, it is of importance to consider additional anti-viral approaches in a combination gene therapy setting. 19, 42 The use of autologous, gene-modified hematopoietic stem cells is an attractive alternative for treatment of HIV-1 infection. For this purpose, HIV-1-derived VSV-G pseudotyped lentiviral vectors have received the most attention.
Currently, lentiviral vectors represent one of the most popular choices because of their ability to transduce nondividing hematopoietic stem cells. We have shown that a single lentiviral vector harboring a triple combination of an shRNA targeting HIV-1 tat/rev mRNAs combined with two HIV-specific RNA-based inhibitors (a CCR5 targeting hammerhead ribozyme and a nucleolar-localized TAR element that serves as a Tat decoy) efficiently suppressed HIV-1 replicated over 42 days and was more effective than a single anti-tat/rev shRNA or double combinations of the shRNA/ribozyme or decoy. 19 This lentiviral vector harboring the three RNA-based anti-HIV moieties has been used for ex vivo gene delivery to hematopoietic stem cells in a first human clinical trial. 43 In this case, after autologous [44] [45] [46] A foamy virus vector has been engineered with a combination of anti-HIV shRNAs and the C46 fusion inhibiting peptide and shown to provide potent protection from HIV infection in a humanized mouse model. The use of a nonintegrating viral vector such as AAV may in the future prove to be useful for transduction of shRNAs into T lymphocytes for ex vivo applications.
CONCLUDING REMARKS
Within the past decade, RNAi has shown great potential as a therapeutic modality for various diseases. HIV-1 became one of the first infectious agents targeted by RNAi because of its wellunderstood life cycle and pattern of gene expression. However, two major obstacles for the long-term use of RNAi against chronic HIV-1 infection are viral escape and poor cellular uptake/stability of siRNA.
Currently, significant progress has been made to identify therapeutic targets and in the development of efficient and safe siRNA delivery approaches. Efforts have been undertaken to identify hundreds of cellular targets and to develop combination therapies. Moreover, several examples discussed in this article demonstrate celltype-specific, nonviral-mediated siRNA delivery into HIV-1-infected and target cells. Moreover, viral vector-mediated multi-RNAi therapeutic approaches may provide a complementary mechanism for combining the power of RNAi with other nucleic acid therapeutics, thereby providing a versatile technology platform for the treatment of various diseases.
RNAi technology still requires refinements before its full potential can be utilized for the routine clinical treatment of HIV. For example, when targeting host-dependency factors, the safety and toxicity profiles of downregulating these host targets must be carefully investigated in long-term knockdown studies. In addition, further efforts should be conducted to refine siRNA delivery schemes and to reduce or avoid unwanted immunogenicity and side effects.
